Cushing's disease (CD) is a rare disabling condition caused by Adrenocorticotropic hormone (ACTH)-secreting adenomas of the pituitary. The majority of corticotropic adenomas are monoclonal and occur sporadically. Only rarely does CD arise in the context of genetic familial syndromes. Targeted sequencing of oncogenes and tumour suppressor genes commonly mutated in other tumours did not identify recurrent mutations. In contrast, next generation sequencing allowed us recently to clarify the genetic basis of CD: we identified somatic driver mutations in the ubiquitin-specific protease 8 (USP8) gene in a significant portion of corticotropinomas. These mutations represent a novel and unique mechanism leading to ACTH excess. Inhibition of USP8 or its downstream signalling pathways could represent a new therapeutic approach for the management of CD. In this review, we will focus on this new evidence and its implication for clinical care of affected patients.
| INTRODUCTION
Cushing′s disease (CD) is a rare devastating condition leading to chronic hypercortisolism. It is caused by Adrenocorticotropic hormone (ACTH)-secreting tumours (corticotropinomas) of the pituitary gland. With an incidence of 1.2-1.7 cases per million per year, its epidemiology is consistent with a classical rare disease.
1 CD is associated with increased morbidity and mortality, the latter mainly due to cardiovascular events.
2
Pituitary adenomas are mainly monoclonal neoplasms. 3 The genetic basis of CD was unclear until recently when recurrent activating somatic driver mutations in the ubiquitin-specific protease 8 gene (USP8)
were identified in almost half of corticotropinomas. [4] [5] [6] [7] [8] Based on this evidence, the pathophysiology of CD has become much clearer. In addition, identification of driver mutations opens up novel diagnostic and therapeutic options for CD. Abbreviations which are used throughout the text are defined in the appendix at the end of the article.
| Mechanisms of tumorigenesis
Corticotropinomas are characterized by altered expression of proteins regulating cell cycle progression. Overexpression of several cyclins has been frequently documented in pituitary adenomas, with overexpression of cyclin E (CCNE1) being specific for corticotropinomas.
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In contrast, cyclin-dependent kinase inhibitors such as p16/Ink4a and p27/Kip1 are downregulated in these tumours. [10] [11] [12] In particular, p27/ Kip1 protein is dramatically reduced in the majority of corticotropinomas. 13 None of the factors that regulate p27 translation and could explain its downregulation at protein but not transcript level, such as dyskeratosis congenita (DKC1)/Dyskerin, ribosomal protein S13 (RPS13), miR221 and miR222, are deregulated in corticotropinomas.
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A recent study using quantitative real time PCR showed decreased transcripts for cyclin D1 and CCNE1 and increased for p16/Ink4 in the 10 CD tumours compared to 11 silent corticotropinomas and 22 nonfunctioning pituitary adenomas.
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Of particular interest for corticotroph tumorigenesis is the CDK5 and ABL1 enzyme substrate 1 (CABLES1), a tumour suppressor that negatively regulates cell cycle by inactivation of several CDKs.
CABLES1 immunoreactivity is lost or severely downregulated in more than half of CD tumours, and this correlates with the loss of p27/ kip1 protein. 16 As CABLES1 stabilizes the cell cycle inhibitors p21/ Cip1 and p27/Kip1, its loss may contribute to development of corticotropinomas, by downregulation of p27/kip1 and destabilization of p21/cip1. 16 Another important growth factor family that is involved in differentiation and tumorigenesis is the fibroblast growth factors (FGFs).
FGF is released from pituitary tumour cells including corticopinomas.
21
The FGF receptor 4 is overexpressed in CD. 22 Functional FGFR4 polymorphisms have been linked either to silent macrocorticotropinomas (R388) or to small hormonally active CD tumours (G388). 23 The FGFR-G388 was associated with lower postoperative remission rate in patients with CD. 
| POMC regulation
POMC transcription is triggered by hypothalamic stimuli in the form of CRH and vasopressin. CRH receptor (CRHR1) is overexpressed in CD tumours compared to silent corticotropinomas. 42 Corticotroph tumours express vasopressin V2 and V3 receptors (V2R and V3R), and no mutations were found in the gene encoding for V3R. 43, 44 Interestingly, VR1b was recently found to be the predominant receptor, suggesting that VR1b antagonists could be useful in the management of CD.
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There is evidence that ACTH synthesis is also regulated by itself in an auto-feedback loop. Indeed, ACTH receptor is expressed in the normal pituitary, but lost in around 70% of corticotropinomas; interestingly, the tumours that did express the receptor had lower ACTH levels. 46 The stimulatory action of CRH on POMC transcription is mediated by several factors. The nerve growth factor IB or Nur77 is in the crossroad of both the stimulatory CRH and the inhibitory glucocorticoid feedback, and its transcript levels are higher in patients with overt CD compared to subclinical CD. 47 Another factor, the nuclear receptor testicular orphan receptor 4 (TR4 nuclear receptor subfamily 2, group C, member 2), binds to the POMC promoter and stimulates its transcription. TR4 is highly expressed in human corticotropinomas, and its overexpression in vitro and in vivo (xenografts) increased ACTH secretion and tumour growth. 48 Interestingly, TR4 was found to attenuate glucocorticoid-induced POMC suppression by physically interacting with glucocorticoid receptor (GR). 
| Glucocorticoid resistance
Resistance to the physiological negative feedback loop of the glucocorticoids to ACTH synthesis is a hallmark of CD. 50 However, genetic defects in the NR3C1 gene encoding for GR are rarely documented in CD. No mutations were reported in the coding and exon-intron boundary region of NR3C1 in 18 corticotropinomas. 51, 52 Two polymorphisms were found in 4 tumours but did not correlate with tumour size or clinical course. A heterozygous frame shift somatic mutation in the GR gene was reported in a patient with Nelson's syndrome and, interestingly, a heterozygous missense germline mutation was reported in a patient affected by glucocorticoid resistance syndrome, who developed CD at the age of 38 years. 53, 54 Other studies on glucocorticoid resistance have focused on the transcriptional regulation of POMC repression by GR. Brahma-related gene 1 (Brg1) and histone deacetylase HDAC2, 2 regulators of chromatin remodelling, are downregulated in corticotropinomas, and this compromises the ability of glucocorticoids to repress POMC transcription resulting in glucocorticoid resistance. 55, 56 Deregulated cortisol metabolism in corticotropinoma cells could also contribute to resistance: CD tumours express high levels of 11-β-hydroxysteroid dehydrogenase 2 (11β-HSD2) that inactivates cortisol to cortisone.
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The shuttling of ligand-bound GR to the nucleus and hence its transcriptional activation are tightly regulated by chaperons like the 90 kDa heat-shock protein HSP90. A recent study showed HSP90 overexpression in corticotropinomas that impaired the ability of glucocorticoids to repress POMC transcription and contributed to the glucocorticoid resistance. Interestingly, the C-terminal HSP90 inhibitor silibinin, which allows the separation of GR from HSP90, restored GR transcriptional activity and glucocorticoid sensitivity and ameliorated CD in vitro and in vivo.
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A study comparing transcript levels of important in corticotroph pathophysiology factors between CD and silent corticotroph tumours showed that CD tumours overexpress CRHR1, V1bR, 11β-HSD2 and the prohormone convertases 1 and 3 (PC1/3) that cleave the POMC prohormone but did not detect differences in GRα expression. 59 Further separating the CD tumours in micro-and macroadenomas revealed that these differences in expression are evidenced only in microcorticotropinomas. 60 Table 1 summarizes genes and proteins deregulated in CD.
| Genetic syndromes associated with CD
CD rarely arises in the context of genetic familial syndromes (Table 2) .
Below, we list the few cases that were reported in the literature.
| MEN 1 syndrome
Multiple endocrine neoplasia (MEN) 1 is characterized by primary hyperparathyroidism, pituitary adenomas and neuroendocrine tumours.
The driver mutation is an inactivating mutation of the MEN 1 suppressor gene that encodes for menin. Menin regulates p27/kip1 and cyclin-dependent kinase subunit 4 (CDK4) and inhibits cell cycle progression at G1. The prevalence of pituitary adenomas in MEN1 ranges between 30% and 40% with PRL-and GH-secreting pituitary adenomas being the most frequent, whereas corticotropinomas are rarely found in MEN 1.
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In a comprehensive multicentre study of 324 patients with MEN1
syndrome, 136 pituitary adenomas were identified, of which only 6
were corticotropinomas: 3 sporadic and 3 unrelated subjects in familiar MEN1 setting. Three were macroadenomas (1 invasive), and 3 patients had persistent cortisol hypersecretion despite treatment. 62 Another retrospective series of around 400 patients with MEN 1 syndrome reported 11 patients with corticotropinoma. The majority had microcorticotropinomas, and most of them were cured by transsphenoidal surgery; interestingly, 3 of 11 patients presented with additional noncorticotroph pituitary tumours. 63 CD was also reported in a MEN1 patient with concomitant microcorticotropinoma and corticotrophinreleasing hormone producing thymic carcinoma. 64 An extremely rare combination of MEN1 and corticotropinoma was reported in 2 Brazilian siblings, who had early-onset CD.
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Corticotropinomas in paediatric patients with MEN1 syndrome have been rarely described. In 3 paediatric patients aged 11-13 years, a microcorticotropinoma was the first manifestation of MEN1 syndrome. 
| MEN4 syndrome
MEN4 syndrome is a very rare MEN1-like condition caused by a nonsense inactivating mutation in the CDKN1B gene (cyclin-dependent kinase inhibitor 1B) coding for p27/Kip1. 71 Most studies showed no mutations in the CDKN1B gene in patients with CD, including paediatric. 67, 72, 73 Immunohistochemistry revealed the absence p27/kip1
immunoreactivity in 1 patient with malignant corticotropinoma. 72 A CDKN1B germline mutation was only described in a female patient with corticotropinoma, neuroendocrine cervical carcinoma and primary hyperparathyroidism.
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An association between the p27 rs2066827 (V109G) polymorphism and corticotroph tumours was found in a large cohort of 447
Brazilian patients affected by different endocrine tumours, including 91 corticotropinomas. 
| McCune-Albright syndrome (MAS)
McCune-Albright syndrome (MAS) is caused by a mosaicism of activating somatic mutations in the GNAS1 oncogene (guanine nucleotide binding protein, alpha stimulating), encoding for the α subunit of the stimulatory G protein, Gs. Clinical characteristics include polyostotic fibrous dysplasia, café-au-lait skin pigmentation and endocrine glands hyperfunction. However, the hypercortisolism that might occur in these patients is mainly due to adrenal Cushing's syndrome as a consequence of adrenal hyperplasia or adenoma. Only few cases of somatic GNAS1 mutations were reported in corticotroph tumours, including an 11-year-old girl with CD.
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| Carney complex (CNC)
Carney complex (CNC) is caused in 70% of the cases by inactivating mutations in the PRKAR1A gene encoding for the 1 alpha regulatory subunit of the c-AMP-dependent protein kinase A (PKA). 78 Myxomas, spotty skin pigmentation, schwannomas and endocrine tumours classically characterize CNC, while hypercortisolism is ACTH-independent as consequence of adrenal hyperplasia. 79 However, very recently, the first case of ACTH-dependent hypercortisolism secondary to a corticotropinoma was reported in a 31-year-old patient with CNC that presented a de novo heterozygous germline mutation in exon 2 of the PRKAR1A gene and a partial loss of the wild-type allele in the tumour indicative of a loss of heterozygosity. 11ß-HSD, 11-β-hydroxysteroid dehydrogenase type; ACTHR, adrenocorticotropic hormone receptor; BMP4, bone morphogenetic protein 4; Brg1, brahma-related gene 1; CABLES1, CDK5 and ABL1 enzyme substrate 1; CCNE1, cyclin E; CDKN1B, cyclin-dependent kinase inhibitor 1B; CDKN2A, cyclindependent kinase inhibitor 2A; CRHR1 corticotropin-releasing hormone receptor 1; EGFR, epithelial growth factor receptor; FGFR4, Fibroblast growth factor receptor 4; HDAC2, histone deacetylase 2; HSP90, 90 kDa heat-shock protein; IL-6, interleukin 6; LIF, leukaemia inhibitor factor; NEUROD1, neurogenic differentiation factor 1; Nur77, nerve growth factor IB; PAX7, paired box 7; PC1/3, prohormone convertase; PRKCD, protein kinase C delta; PTTG, pituitary tumour transforming gene; SHH, Sonic hedgehog; TR4, testicular orphan receptor 4; VR1b, arginine vasopressin receptor type 1b.
T A B L E 1 Genes/Proteins deregulated in corticotropinomas

| Tuberous sclerosis complex (TSC)
Tuberous sclerosis complex is caused by germline mutations in 2 tumour suppressor genes, TSC1 which encodes for hamartin or TSC2, 
| Dax1
A 33-year-old man with X-linked adrenal hypoplasia congenital, carrying a germline frame shift mutation in the gene encoding for 
| Somatic genetic events
Mutations in known proto-oncogenes or tumour suppressor genes are rarely reported. One study of 3 corticotropinomas and 4 ACTHsecreting carcinomas showed mutations in the p53 gene in 2 of the carcinomas. 92 Another case has been reported of somatic p53 mutation in a patient with an invasive corticotroph tumour and difficult to treat CD.
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In 2015, using next generation sequencing, we discovered a somatic mutational hotspot in the gene encoding for the ubiquitinspecific protease 8 (USP8). 4 An independent investigation in an Asian population identified exactly the same mutational hotspot confirming its importance in CD. 6 Subsequent multicentric studies in large CD cohorts revealed the incidence of USP8 mutation to be between 35% and 60%. [4] [5] [6] [7] [8] The USP8 gene encodes for a deubiquitinase that plays a crucial role in regulating the stability of tyrosine kinases receptors, such as EGFR. All mutations identified so far are located in a hotspot region in exon 14 that binds to the 14-3-3 protein family and therefore impair their binding. Loss of 14-3-3 binding makes USP8 susceptible to proteolytic cleavage and allows the formation of a C-terminal 40-kDa fragment with higher catalytic capacity.
We and other have shown that the activated USP8 deubiquitinates EGFR protecting it from lysosomal degradation, leading to increased EGFR stability and maintaining its downstream signalling pathways in an active state. 4, 6 Investigations in human CD revealed higher EGFR transcript and immunoreactivity in USP8 mutated corticotropinoma cells. 6 A subsequent investigation however, did not detect differences in EGFR expression as determined by immunohistochemistry in USP8 mutant vs wild-type tumours (Figure 1 ). Finally, a recent transcriptomic analysis of 12 corticotropinomas revealed differences between invasive macroadenomas and noninvasive micro/macroadenomas. 98 Among the genes highlighted were cyclin D2 (CCND2) and Zinc-finger 676 protein (ZNF676) that were increased and death-associated protein kinase 1 (DAPK1) and metalloproteinase inhibitor 2 (TIMP2) that were decreased in the invasive CD tumours.
| CONCLUSIONS
In the last few years, major progress has been made to better un- wild-type corticotropinomas will likely be identified using NGS. We do not expect to identify a second major mutational hotspot like USP8, but rather low-frequency mutational events. This might be similar to the outcome of exome sequencing in GH-secreting pituitary tumours that confirmed in 40% of cases the known mutations in the GNAS encoding for the stimulatory G protein alpha subunit and showed mutations in single genes in the rest of the cases, rather than another mutational hotspot. 99 These genes, however, when considered together highlight the "addiction" of acromegalic tumours to the c-AMP and calcium signalling pathways. Similarly, we expect that our efforts will highlight pathways that drive and sustain corticotroph tumour formation. This will ultimately, more than 100 years after the description of the first patient, Minnie G.,
by Harvey Cushing solve the genetic riddle of this disease. 
